An oncolytic reovirus-based platform amenable to oral vaccination

Vaccines have long been the most powerful tool humanity possesses against infectious diseases and cancer, yet their delivery often relies on needles and refrigeration, creating barriers for people in remote areas or those who fear injections. Furthermore, many standard vaccines are designed to travel through the bloodstream to generate a body-wide defense, but they often struggle to create a strong shield at the body's entry points, such as the lining of the gut or lungs, where many viruses first invade and where certain cancers frequently begin. Scientists have been searching for a way to trigger a robust immune response through the mouth, a method that would be easy to administer and naturally target these vulnerable mucosal surfaces, but the harsh environment of the digestive system has made this a difficult engineering challenge.

In a new study, researchers have developed a promising solution using a virus that is naturally adapted to survive the human gut. They engineered a harmless version of a reovirus, a virus that naturally infects the intestines, to act as a delivery vehicle for specific disease-fighting instructions. By swapping out a part of the virus's outer shell that usually helps it stick to cells, they replaced it with pieces of proteins from other threats, such as a model cancer protein or a part of the coronavirus. This modified virus was designed to be safe, unable to cause disease in healthy people, but potent enough to wake up the immune system. The researchers found that when this virus was given orally, it successfully navigated the stomach and intestines to train the body's immune cells, creating a dual defense system that protected against both the specific virus it carried and the cancer it was programmed to target.

The team began by taking a live, weakened form of the reovirus known as T3D and genetically reprogramming its surface. They removed a specific section of the virus's outer protein, which normally acts like a key to open cells, and inserted genetic instructions for foreign antigens in its place. These antigens included ovalbumin, a common protein used in research, and the receptor-binding domain of the SARS-CoV-2 virus, which is the part of the coronavirus that latches onto human cells. The goal was to create a virus that could display these foreign targets on its surface while remaining stable enough to survive the acidic conditions of the stomach. The researchers confirmed that these engineered viruses could still replicate inside cells and produce the new proteins on their surface, effectively turning the virus into a moving billboard for the immune system to recognize.

To test if this approach worked, the scientists administered the engineered viruses to mice through different methods, including injections and oral gavage, which mimics swallowing a pill or liquid. They discovered that all routes of delivery successfully triggered a strong immune response, producing antibodies and activating T cells, which are the body's specialized soldiers that hunt down infected or cancerous cells. However, the oral route produced a unique and critical advantage: it generated high levels of IgA antibodies. These are a specific type of antibody that coats the mucous membranes of the gut and lungs, providing a first line of defense exactly where many pathogens enter the body. This suggested that the oral vaccine was not just creating a general immune response but was specifically fortifying the body's entry points.

The researchers then tested whether this immune training could prevent cancer. They used a mouse model of melanoma, a type of skin cancer, that had been genetically modified to display the same protein the virus was carrying. Mice that received the oral vaccine were protected from developing tumors when they were later exposed to the cancer cells. In fact, the vaccine was so effective that it prevented the cancer from taking hold entirely in many cases. When the researchers looked at the lungs of mice that had been given the cancer cells intravenously to simulate metastasis, the vaccinated mice showed a dramatic reduction in tumor growth compared to unvaccinated controls. The immune system, primed by the oral virus, recognized the cancer cells as invaders and eliminated them before they could spread.

A crucial part of the study was determining how this protection worked. The scientists wanted to know if the virus simply needed to be present to show the immune system the target, or if the virus needed to actively replicate and multiply inside the body to be effective. They tested this by using a version of the virus that had been killed with ultraviolet light, rendering it unable to reproduce. When they gave this dead virus to mice, it failed to protect them from cancer. This finding proved that the virus must be alive and replicating to generate the necessary immune response. The active replication appears to be essential for the virus to act as a potent adjuvant, a substance that boosts the body's reaction to the vaccine, ensuring the immune system pays close attention to the new targets it is being shown.

The study also addressed a common concern in virus-based therapies: what happens if a person has already been exposed to the virus naturally? Reovirus is very common in the human population, and many people already have antibodies against it. The researchers tested whether this pre-existing immunity would block the vaccine's effectiveness. They gave mice a series of doses of the natural virus to simulate prior exposure and then vaccinated them with the engineered version. Surprisingly, the pre-existing immunity did not stop the vaccine from working. The engineered virus was still able to replicate enough to trigger a strong immune response against the cancer, suggesting that this platform could be effective even in populations where the virus is already widespread.

Finally, the team explored whether this vaccine could work in combination with other treatments. They found that when the oral vaccine was paired with a type of therapy known as immune checkpoint blockade, which helps the immune system overcome the defenses cancer uses to hide, the results were even more powerful. The combination led to a significant increase in survival rates for mice with established tumors, far better than either treatment alone. This suggests that the oral virus vaccine could sensitize tumors to other therapies, making them more vulnerable to attack. The researchers concluded that this platform offers a versatile and accessible way to deliver vaccines, capable of inducing both systemic and mucosal immunity without the need for needles or cold storage, potentially opening new doors for preventing infectious diseases and treating cancers that arise in the gut and lungs.